FDA orders halt to marketing of unapproved single-ingredient oral colchicine

Drug commonly used to prevent gout, treat gout flares, and treat Familial Mediterranean Fever (FMF)

The U.S. Food and Drug Administration today took action against companies that manufacture, distribute, and/or market unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of Familial Mediterranean Fever (FMF).